Watermark
  Back to Search Results

BGB-A317-303

Completed

Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)

BeOne Study ID Info icon SVG graphic used for tooltips or additional information.

BGB-A317-303

ClinicalTrials.gov ID Info icon SVG graphic used for tooltips or additional information.

NCT03358875

EudraCT or EUCT Number Info icon SVG graphic used for tooltips or additional information.

2018

China Drug Trials ID Info icon SVG graphic used for tooltips or additional information.

CTR20171112

Study Overview

Sex: All Info icon SVG graphic used for tooltips or additional information.

Age: 18 Years / N/A

Accepts Healthy Volunteers? No

Study Documents

Study Protocol Statistical Analysis Plan Plain Language Summary

Study Overview

Sex: All Info icon SVG graphic used for tooltips or additional information.

Age: 18 Years / N/A

Accepts Healthy Volunteers? No

Study Documents

Study Protocol Statistical Analysis Plan Plain Language Summary